Insider Transactions in Q2 2022 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Matthew E Korenberg President & COO |
BUY
Other acquisition or disposition
|
Direct |
164
+0.31%
|
$12,300
$75.84 P/Share
|
|
Jun 30
2022
|
John L Higgins Director |
BUY
Other acquisition or disposition
|
Direct |
164
+0.04%
|
$12,300
$75.84 P/Share
|
|
Jun 29
2022
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+50.0%
|
-
|
|
Jun 10
2022
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+3.71%
|
-
|
|
Jun 10
2022
|
Matthew E Korenberg President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,062
+13.34%
|
-
|
|
Jun 10
2022
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,423
+5.24%
|
-
|
|
Jun 10
2022
|
Matthew W Foehr |
BUY
Grant, award, or other acquisition
|
Direct |
9,137
+4.77%
|
-
|
|
Jun 10
2022
|
Charles S Berkman |
BUY
Grant, award, or other acquisition
|
Direct |
5,375
+13.06%
|
-
|
|
Jun 10
2022
|
Sunil Patel |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+3.26%
|
-
|
|
Jun 10
2022
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+3.66%
|
-
|
|
Jun 10
2022
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+2.32%
|
-
|
|
Jun 10
2022
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+17.58%
|
-
|
|
Jun 10
2022
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+1.9%
|
-
|
|
Jun 10
2022
|
Jennifer R. Cochran |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+31.68%
|
-
|
|
Jun 10
2022
|
Sarah Boyce |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+20.49%
|
-
|
|
Jun 10
2022
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,004
+1.42%
|
-
|
|
May 13
2022
|
Matthew W Foehr |
BUY
Open market or private purchase
|
Direct |
2,500
+1.42%
|
$205,000
$82.76 P/Share
|
|
May 09
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.24%
|
$168,000
$21.92 P/Share
|